Ubiquitin-proteasome pathway and prostate cancer

Onkologie(Czech Republic)

Volumn 36, Issue 10, 2013, Pages 592-596

  Chen, Fang Zhi ^a   Zhao, Xiao Kun ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Prostate cancer; Targeted cancer therapy; Ubiquitin like modifier proteins; Ubiquitin proteasome system

Indexed keywords

ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; BORTEZOMIB; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEASOME; PROTEASOME INHIBITOR; TRANSCRIPTION FACTOR SLUG; UBIQUITIN;

ANGIOGENESIS; APOPTOSIS; CANCER CELL; CELL ADHESION; CELL CYCLE REGULATION; DOWN REGULATION; DRUG POTENTIATION; HUMAN; PROSTATE CANCER; PROTEIN DEGRADATION; REVIEW; TUMOR GROWTH; UBIQUITINATION;

ANIMALS; HUMANS; MALE; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; PROSTATE; PROSTATIC NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; UBIQUITIN;

EID: 84885651936     PISSN: 0378584X     EISSN: 14230240     Source Type: Journal    
DOI: 10.1159/000355166     Document Type: Review

References (47)

1. Yamamura M, Hirai T, Yamaguchi Y: Proteasome inhibitor. Nihon Rinsho 2010;68:1079-1084.
2. Melvin AT, Woss GS, Park JH, Waters ML, Allbritton NL: Measuring activity in the ubiquitinproteasome system: from large scale discoveries to single cells analysis. Cell Biochem Biophys 2013; Epub ahead of print.
3. Zhang J, Wu P, Hu Y: Clinical and marketed proteasome inhibitors for cancer treatment. Curr Med Chem 2013;20:2537-2551.
4. Myung J, Kim KB, Crews CM: The ubiquitin-proteasome pathway and proteasome inhibitors. Med Res Rev 2001;21:245-273.
5. Pickart CM: Mechanisms underlying ubiquitination. Annu Rev Biochem 2001;70:503-533.
6. Lecker SH, Goldberg AL, Mitch WE: Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. J Am Soc Nephrol 2006;17:1807-1819.
7. Tu Y, Chen C, Pan J, Xu J, Zhou ZG, Wang CY: The ubiquitin proteasome pathway (UPP) in the regulation of cell cycle control and DNA damage repair and its implication in tumorigenesis. Int J Clin Exp Pathol 2012;5:726-738.
8. Sadowski M, Suryadinata R, Tan AR, Roesley SN, Sarcevic B: Protein monoubiquitination and polyubiquitination generate structural diversity to control distinct biological processes. IUBMB Life 2012;64:136-142.
9. Brinkman M, Reulen RC, Kellen E, Buntinx F, Zeegers MP: Are men with low selenium levels at increased risk of prostate cancer? Eur J Cancer 2006;42:2463-2471.
10. Farrell J, Petrovics G, McLeod DG, Srivastava S: Genetic and molecular differences in prostate carcinogenesis between African American and Caucasian American men. Int J Mol Sci 2013;14: 15510-31.
11. Siegel R, Naishadham D, Jemal A: Cancer statistics. CA Cancer J Clin 2013;63:11-30.
12. Baade PD, Youlden DR, Krnjacki LJ: International epidemiology of prostate cancer: geographical distribution and secular trends. Mol Nutr Food Res 2009;53:171-184.
13. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, et al.: Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360:1310-1319.
14. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al.: Screening and prostate- cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-1328.
15. Kellokumpu-Lehtinen P, Tammela T: Novel drugs provide better therapy for prostate cancer. Duodecim 2013;129:923-930.
16. Schrader AJ, Boegemann M, Ohlmann CH, Schnoeller TJ, Krabbe LM, Hajili T, Jentzmik F, Stoeckle M, Schrader M, Herrmann E, Cronauer MV: Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. Eur Urol 2013;Epub ahead of print.
17. Linja MJ, Porkka KP, Kang Z, Savinainen KJ, Janne OA, Tammela TL, Vessella RL, Palvimo JJ, Visakorpi T: Expression of androgen receptor coregulators in prostate cancer. Clin Cancer Res 2004;10:1032-1040.
18. Williamson SC, Hepburn AC, Wilson L, Coffey K, Ryan-Munden CA, Pal D, Leung HY, Robson CN, Heer R: Human á(2)â(1) (HI) CD133(+VE) epi thelial prostate stem cells express low levels of active androgen receptor. PLoS One 2012;7: e48944.
19. Bonaccorsi L, Nosi D, Quercioli F, Formigli L, Zecchi S, Maggi M, Forti G, Baldi E: Prostate cancer: a model of integration of genomic and non- genomic effects of the androgen receptor in cell lines model. Steroids 2008;73:1030-1037.
20. Reddy GP, Barrack ER, Dou QP, Menon M, Pelley R, Sarkar FH, Sheng S: Regulatory processes affecting androgen receptor expression, stability, and function: potential targets to treat hormone-refractory prostate cancer. J Cell Biochem 2006;98:1408-1423.
21. Li H, Xu LL, Masuda K, Raymundo E, McLeod DG, Dobi A, Srivastava S: A feedback loop between the androgen receptor and a NEDD4-binding protein, PMEPA1, in prostate cancer cells. J Biol Chem 2008;283:28988-28995.
22. Xu LL, Shi Y, Petrovics G, Sun C, Makarem M, Zhang W, Sesterhenn IA, McLeod DG, Sun L, Moul JW, Srivastava S: PMEPA1, an androgenregulated NEDD4-binding protein, exhibits cell growth inhibitory function and decreased expression during prostate cancer progression. Cancer Res 2003;63:4299-4304.
23. Qi J, Tripathi M, Mishra R, Sahgal N, Fazli L, Ettinger S, Placzek WJ, Claps G, Chung LW, Bowtell D, Gleave M, Bhowmick N, Ronai ZA: The E3 ubiquitin ligase Siah2 contributes to castration- resistant prostate cancer by regulation of androgen receptor transcriptional activity. Cancer Cell 2013;23:332-346.
24. Sarkar S, Brautigan DL, Parsons SJ, Larner JM: Androgen receptor degradation by the E3 ligase CHIP modulates mitotic arrest in prostate cancer cells. Oncogene 2012;Epub ahead of print.
25. Macri E, Loda M: Role of p27 in prostate carcinogenesis. Cancer Metastasis Rev 1998-1999;17:337-344.
26. Rico-Bautista E, Yang CC, Lu L, Roth GP, Wolf DA: Chemical genetics approach to restoring p27Kip1 reveals novel compounds with antiproliferative activity in prostate cancer cells. BMC Biol 2010;8:153.
27. Lu L, Schulz H, Wolf DA: The F-box protein SKP2 mediates androgen control of p27 stability in LNCaP human prostate cancer cells. BMC Cell Biol 2002;3:22.
28. Liu J, Uygur B, Zhang Z, Shao L, Romero D, Vary C, Ding Q, Wu WS: Slug inhibits proliferation of human prostate cancer cells via downregulation of cyclin D1 expression. Prostate 2010;70:1768-1777.
29. Ding GX, Liu J, Feng CC, Jiang HW, Xu JF, Ding Q: Slug regulates cyclin D1 expressionin by ubiquitin-proteasome pathway in prostate cancer cells. Panminerva Med 2012;54:219-223.
30. Li B, Dou QP: Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression. Proc Natl Acad Sci U S A 2000;97:3850-3855.
31. Singh G, Chan AM: Post-translational modifications of PTEN and their potential therapeutic implications. Curr Cancer Drug Targets 2011;11:536-547.
32. Song MS, Carracedo A, Salmena L, Song SJ, Egia A, Malumbres M, Pandolfi PP: Nuclear PTEN regulates the APC-CDH1 tumor-suppressive com-epiplex in a phosphatase-independent manner. Cell 2011;144:187-199.
33. Trotman LC, NikiM, Dotan ZA, Koutcher JA, Di Cristofano A, Xiao A, Khoo AS, Roy-Burman P, Greenberg NM, Van Dyke T, Cordon-Cardo C, Pandolfi PP: PTEN dose dictates cancer progression in the prostate. PLoS Biol 2003;1:E59.
34. Wang X, Jiang X: Post-translational regulation of PTEN. Oncogene 2008;27:5454-5463.
35. Ahmed SF, Deb S, Paul I, Chatterjee A, Mandal T, Chatterjee U, Ghosh MK: The chaperone-Assisted E3 ligase C terminus of Hsc70-interacting protein (CHIP) targets PTEN for proteasomal degradation. J Biol Chem 2012;287:15996-16006.
36. Wu F, Mo YY: Ubiquitin-like protein modifications in prostate and breast cancer. Front Biosci 2007; 12:700-711.
37. Bawa-Khalfe T, Yeh ET: SUMO losing balance: SUMO proteases disrupt SUMO homeostasis to facilitate cancer development and progression. Genes Cancer 2010;1:748-752.
38. Dunn B: Cancer: solving an age-old problem. Nature 2012;483:S2-S6.
39. Herrmann JL, Briones F Jr, Brisbay S, Logothetis CJ, McDonnell TJ: Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53. Oncogene 1998;17:2889-2899.
40. Whang PG, Gamradt SC, Gates JJ, Lieberman JR: Effects of the proteasome inhibitor bortezomib on osteolytic human prostate cancer cell metastases. Prostate Cancer Prostatic Dis 2005;8:327-334.
41. Cao B, Mao X: The ubiquitin-proteasomal system is critical for multiple myeloma: implications in drug discovery. Am J Blood Res 2011;1:46-56.
42. Lara PN Jr, Davies AM, Mack PC, Mortenson MM, Bold RJ, Gumerlock PH, Gandara DR: Proteasome inhibition with PS-341 (bortezomib) in lung cancer therapy. Semin Oncol 2004;31:40-46.
43. Wei X, DU ZY, Cui XX, Verano M, Mo RQ, Tang ZK, Conney AH, Zheng X, Zhang K: Effects of cyclohexanone analogues of curcumin on growth, apoptosis and NF-?B activity in PC-3 human prostate cancer cells. Oncol Lett 2012;4: 279-284.
44. Killian PH, Kronski E, Michalik KM, Barbieri O, Astigiano S, Sommerhoff CP, Pfeffer U, Nerlich AG, Bachmeier BE: Curcumin inhibits prostate cancer metastasis in vivo by targeting the inflammatory cytokines CXCL1 and -2. Carcinogenesis 2012;33: 2507-2519.
45. Li M, Zhang Z, Hill DL, Wang H, Zhang R: Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway. Cancer Res 2007;67:1988-1996.
46. Cimino S, Sortino G, Favilla V, Castelli T, Madonia M, Sansalone S, Russo GI, Morgia G: Polyphenols: key issues involved in chemoprevention of prostate cancer. Oxid Med Cell Longev 2012;2012: 632959.
47. Aggarwal BB, Banerjee S, Bharadwaj U, Sung B, Shishodia S, Sethi G: Curcumin induces the degradation of cyclin E expression through ubiquitindependent pathway and up-regulates cyclin-dependent kinase inhibitors p21 and p27 in multiple human tumor cell lines. Biochem Pharmacol 2007;73:1024-1032.